NCT02159872View on ClinicalTrials.gov

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 18, 2015

Primary Completion Date

April 14, 2020

Study Completion Date

April 14, 2020

Conditions
Leukemia
Interventions
DRUG

Omacetaxine

1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02159872 - Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure | Biotech Hunter | Biotech Hunter